| abstract |
This disclosure relates to managing diabetic neuropathy using compounds disclosed herein. In certain embodiments, this disclosure relates to methods of treating or preventing vascular conditions such as diabetic neuropathy comprising administering a compound capable of epigenetic modification, such as histone deacetylase inhibitors, to a subject in need thereof. In certain embodiments, this disclosure relates to the use of HDAC inhibitors to treat directly diabetic neuropathies and pain without the use of progenitor cells or stem cells. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnoses with diabetes, diabetic neuropathy, peripheral neuropathy, autonomic neuropathy, radiculoplexus neuropathy, mononeuropathy, diabetic retinopathy, or complications related thereto. In certain embodiments, the compound is selected from belinostat, quisinostat, and vorinostat. |